13F reference period
Q2 2026
Security Snapshot
Senti Biosciences Holdings, Inc. - Common Stock, par value $0.0001 per share (SNTI) Institutional Ownership
CUSIP: 81726A209
13F Institutional Holders and Ownership History from Q3 2024 to Q2 2026
Institutions Reporting
1
Shares (Excl. Options)
3.78M
Full value: 3,775,615 · shares · 30 Jun 2026Price
$1.10
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- SNTI on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 3,775,615
- Total 13F value
- $4,153,177
- Share change
- -1,864,592
- Value change
- -$1,513,998
- Number of holders
- 1
- Shares outstanding
- 47,159,139
- SEC-reported price per share
- $1.10
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- SNTI - Senti Biosciences Holdings, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 81726A209.
- 1 institution reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 16 to 1 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$4.58M
Full value: $4,579,797 · USD · 31 Mar 2026.$4.15M
Full value: $4,153,177 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q2 2026.
Security key
81726A209
13F reference period
Q2 2026
13F holders
1
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
SNTI full holder history
Senti Biosciences Holdings, Inc. SEC filings
Senti Biosciences Holdings, Inc. company facts
Senti Biosciences Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81726A209:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
SNTI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Celadon Partners SPV 24 | 55% | +21% | $23,174,001 | +$11,013,811 | 25,748,890 | +91% | Celadon Partners SPV 24 | 27 Apr 2026 |
| BAYER HEALTHCARE LLC | 18% | $4,729,993 | 6,142,848 | Bayer HealthCare LLC | 27 Mar 2026 | |||
| New Enterprise Associates 15, L.P. | 14% | $11,968,700 | 3,775,615 | New Enterprise Associates 15, L.P. | 06 Mar 2025 | |||
| Nantahala Capital Management, LLC | 8.1% | -19% | $7,037,400 | +$5,422,973 | 2,220,000 | +336% | Nantahala Capital Management, LLC | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $4,564,204 | +$2,865,052 | 1,439,812 | +169% | Armistice Capital, LLC | 31 Mar 2025 |
| Nantahala Capital Partners Limited Partnership | 1.9% | -67% | $1,592,925 | +$637,170 | 502,500 | +67% | NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP | 31 Mar 2025 |
As of 30 Jun 2026,
1
institutional investors reported holding
shares of
Senti Biosciences Holdings, Inc. - Common Stock, par value $0.0001 per share (SNTI).
This represents
8%
of the company’s total
outstanding shares.
3.78M
Full value: 3,775,615 · shares · 30 Jun 202647.16M
Full value: 47,159,139 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Headline period
Q2 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 3,775,615 | $4,153,177 | -$1,513,998 | $1.10 | 1 |
| 2026 Q1 | 5,640,207 | $4,579,797 | +$1,436 | $0.81 | 16 |
| 2025 Q4 | 5,614,365 | $5,838,757 | -$78,561 | $1.04 | 15 |
| 2025 Q3 | 5,609,415 | $7,909,282 | -$2,933,848 | $1.41 | 15 |
| 2025 Q2 | 6,484,682 | $13,682,488 | +$1,724,635 | $2.11 | 14 |
| 2025 Q1 | 5,663,433 | $19,029,155 | +$16,777,530 | $3.36 | 14 |
| 2024 Q4 | 667,184 | $2,341,958 | -$330,207 | $3.51 | 14 |
| 2024 Q3 | 763,984 | $1,726,485 | +$1,717,436 | $2.26 | 12 |